ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Sign Up

Already a member? Sign in

Interactive Brokers

Interactive Brokers
Market Data
News
Trading Tools
Markets
Discover

Hot Features

Follow Feed

Connect with traders and investors in our Follow Feed community.

Options Flow

Explore comprehensive options data and use advanced filters with Options Flow.

Monitor

Organize and monitor your stock and asset watchlist with Monitor.
AI Sign In Premium IconPremium Help Menu
S&P 500
6,008.58
0.59%
US Tech 100
20,582.80
0.20%
Dow Jones
44,086.74
0.82%
Brent Oil
73.80
-2.20%
Bitcoin
77,090.08
1.56%
Registration Strip Icon for tools Level up your trading with our powerful tools and real-time insights all in one place.
Get Started
  1. Home
  2. Investing
  3. Stocks
  4. USA
  5. NASDAQ

  6. Krystal Biotech Inc (KRYS) Quote

Krystal Biotech Inc

Krystal Biotech Inc (KRYS)

NASDAQ
195.15
9.70
( 5.23% )
Updated: 14:12:50
Delayed by 15 minutes

Real-time discussions and trading ideas: Trade with confidence with our powerful platform.

Premium

Key stats and details

Current Price
195.15
Bid
194.46
Ask
195.39
Volume
206,179
184.855 Day's Range 197.98
93.95 52 Week Range 219.34
Market Cap
5.607B
Previous Close
185.45
Open
184.87
Last Trade
1
@
195.0346
Last Trade Time
14:13:38
Financial Volume
$ 39,611,037
VWAP
192.1197
Average Volume (3m)
213,794
Shares Outstanding
28,729,950
Dividend Yield
-
PE Ratio
513.17
Earnings Per Share (EPS)
0.38
Revenue
50.7M
Net Profit
10.93M

About Krystal Biotech Inc

Krystal Biotech Inc is engaged in the healthcare sector in the United States. It is focused on development of easy to use, redosable gene therapies to improve the lives of patients living with debilitating diseases. The company used its proprietary gene therapy platform, STAR-D to develop treatments... Krystal Biotech Inc is engaged in the healthcare sector in the United States. It is focused on development of easy to use, redosable gene therapies to improve the lives of patients living with debilitating diseases. The company used its proprietary gene therapy platform, STAR-D to develop treatments for rare or orphan dermatological indications caused by the absence of or a mutation in a single gene. It plans to leverage its platform to expand its pipeline to include other dermatological indications in the future. Show more

Sector
Biological Pds,ex Diagnstics
Industry
Biological Pds,ex Diagnstics
Website
www.krystalbio.com
Headquarters
Wilmington, Delaware, USA
Founded
-
Krystal Biotech Inc is listed in the Biological Pds,ex Diagnstics sector of the NASDAQ with ticker KRYS. The last closing price for Krystal Biotech was $185.45. Over the last year, Krystal Biotech shares have traded in a share price range of $ 93.95 to $ 219.34.

Krystal Biotech currently has 28,729,950 shares outstanding. The market capitalization of Krystal Biotech is $5.33 billion. Krystal Biotech has a price to earnings ratio (PE ratio) of 513.17.

Ask ADVFN Intelligence (AI)

Krystal Biotech (KRYS) Options Flow Summary

KRYS Options Flow

Overall Flow

Bullish

Net Premium

2M

Calls / Puts

100.00%

Buys / Sells

50.00%

OTM / ITM

100.00%

Sweeps Ratio

0.00%

KRYS Latest News

More News

Krystal Biotech to Present at Guggenheim Securities Healthcare Innovation Conference

PITTSBURGH, Nov. 06, 2024 (GLOBE NEWSWIRE) -- Krystal Biotech, Inc. (the “Company”) (NASDAQ: KRYS), a commercial-stage biotechnology company, today announced that the Company will participate in...

November 06 2024
GlobeNewswire Inc.

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

November 04 2024
Edgar (US Regulatory)

Form 8-K - Current report

November 04 2024
Edgar (US Regulatory)

Krystal Biotech Announces Third Quarter 2024 Financial Results and Provides Business Updates

Net product revenue of $83.8 million in 3Q and $250.1 million since launch in August 2023 JNDA for B-VEC filed and on track for commercial launches in Japan and Europe in 2025 French health...

November 04 2024
GlobeNewswire Inc.

Krystal Biotech to Report Third Quarter 2024 Financial Results on November 4, 2024

PITTSBURGH, Oct. 28, 2024 (GLOBE NEWSWIRE) -- Krystal Biotech, Inc. (the “Company”) (NASDAQ: KRYS), a commercial-stage biotechnology company, today announced that it will report its third...

October 28 2024
GlobeNewswire Inc.

Krystal Biotech to Present at 2024 Cantor Global Healthcare Conference

PITTSBURGH, Sept. 13, 2024 (GLOBE NEWSWIRE) -- Krystal Biotech, Inc. (the “Company”) (NASDAQ: KRYS), a commercial-stage biotechnology company, today announced that the Company will participate...

September 13 2024
GlobeNewswire Inc.

Krystal Biotech to Present at H.C. Wainwright 26th Annual Global Investment Conference

PITTSBURGH, Sept. 06, 2024 (GLOBE NEWSWIRE) -- Krystal Biotech, Inc. (the “Company”) (NASDAQ: KRYS), a commercial-stage biotechnology company, today announced that the Company will participate...

September 06 2024
GlobeNewswire Inc.

Form 8-K - Current report

August 28 2024
Edgar (US Regulatory)

Jeune Aesthetics Announces Phase 1 Positive Interim Safety and Efficacy Results for KB301 in the Treatment of Lateral Canthal Lines and Dynamic Wrinkles of the Décolleté

Décolleté indication selected for Phase 2 study expected to start next year Conference call to discuss results scheduled for Wednesday, August 28, 2024 at 4:30 p.m. ET PITTSBURGH, Aug. 28, 2024...

August 28 2024
GlobeNewswire Inc.

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

August 05 2024
Edgar (US Regulatory)
PeriodChangeChange %OpenHighLowAvg. Daily VolVWAP
122.1212.7839103046173.03197.98163.6641429602176.82076665CS
421.8212.5887036289173.33197.98163.6641209409176.74052005CS
121.690.873565594955193.46206.97163.6641213794184.34659502CS
2635.0821.9154120072160.07219.34154.48301174182.10884208CS
5286.3279.3163649729108.83219.3493.95326200159.42085874CS
156142.43270.16312594852.72219.3438.8563275734114.63583175CS
260153.28366.08550274741.87219.3433.084822386599.00249593CS

Movers

View all
  • Most Active
  • % Gainers
  • % Losers
SymbolPriceVol.
SEZLSezzle Inc
$ 440.00
(75.67%)
441.86k
INODInnodata Inc
$ 41.44
(70.25%)
7.74M
AAOIApplied Optoelectronics Inc
$ 27.175
(51.82%)
15.2M
INDIindie Semiconductor Inc
$ 5.19
(51.31%)
29.28M
PRCHPorch Group Inc
$ 3.5135
(50.79%)
13.83M
PRPHProPhase Labs Inc
$ 0.7829
(-45.25%)
2.1M
NXUNXU Inc
$ 0.3052
(-43.04%)
7.07M
MRVIMaravai LifeSciences Holdings Inc
$ 4.775
(-39.09%)
7.84M
RVNCRevance Therapeutics Inc
$ 3.545
(-38.67%)
10.34M
ALVRAlloVir Inc
$ 0.6175
(-37.09%)
1.62M
ELABElevai Labs Inc
$ 0.01975
(10.34%)
371.51M
TIVCTivic Health Systems Inc
$ 0.3941
(51.29%)
264.06M
TSLATesla Inc
$ 324.6038
(9.33%)
141.24M
TSLLDirexion Daily TSLA Bull 2X Trust ETF
$ 19.4399
(18.61%)
140.41M
WBUYWeBuy Global Ltd
$ 0.2788
(22.71%)
132.94M

KRYS Discussion

View Posts
Monksdream Monksdream 2 weeks ago
KRYS. Under $200
👍️0
Monksdream Monksdream 3 months ago
KRYS new 52 week high
👍️0
Monksdream Monksdream 6 months ago
KRYS 10Q due 5/6
👍️0
Monksdream Monksdream 7 months ago
KRYS over $30
👍️0
Monksdream Monksdream 8 months ago
KRYS new 52 week high
👍️0
Monksdream Monksdream 1 year ago
From Cathie Wood
A Novel Gene Therapy Promises Relief For A Rare Genetic Skin Disorder
ARK Invest_Illustration_Pierce Jamieson_Final_Circle 400 px By Pierce Jamieson | @PierceARK
Research Associate
Recently, the US Food and Drug Administration (FDA) approved Krysta Biotech’s (KRYS) groundbreaking advance1 in gene therapy, Vyjuvek, to treat wounds in patients suffering from dystrophic epidermolysis bullosa (DEB), a rare and serious genetic skin disorder caused by mutations in the collagen Type VII alpha 1 chain (COL7A1) gene. As the first FDA-approved gene therapy for DEB, Vyjuvek is a significant breakthrough.

Vyjuvek uses a genetically modified HSV-1 to deliver normal copies of the COL7A1 gene to wounds, restoring the integrity of the skin with fibrils that hold skin layers together. Treated with Vyjuvek, 65% of wounds closed completely.
👍️0
wiredawg wiredawg 3 years ago
Moving nicely today...
👍️0
wiredawg wiredawg 3 years ago
Looking at the few posts here there seems to be no real commitment here...any thoughts on KRYS? Hype or something brewing?
👍️0
wiredawg wiredawg 3 years ago
In the last 3 months, 5 ranked analysts set 12-month price targets for KRYS. The average price target among the analysts is $125.00. Analysts compare their price target to the current market price of the stock to determine how much potential upside or downside movement there could be in the stock price. High $140 Low $111

👍️0
wiredawg wiredawg 3 years ago
30 Nov Tues releases this PR during evening after market close:

https://ir.krystalbio.com/news-releases/news-release-details/krystal-biotech-announces-pricing-200-million-public-offering
👍️0
wiredawg wiredawg 3 years ago
29 Nov Mon after market closes release this PR:

https://ir.krystalbio.com/news-releases/news-release-details/krystal-biotech-announces-proposed-200-million-public-offering
👍️0
wiredawg wiredawg 3 years ago
29 Nov Monday pre-market news release, great move pre-market approx 7am and so far holding fairly well:

https://ir.krystalbio.com/news-releases/news-release-details/krystal-biotech-announces-positive-topline-results-gem-3-pivotal
👍️0
wiredawg wiredawg 3 years ago
This caught my eye on Monday, the huge move off the PR...I'm guessing here saw the same. Any real thoughts regarding the company and this PR. I have not gotten a chance to dig into it. Hoping to have somm DD done over the weekend.
👍️0
wiredawg wiredawg 3 years ago
Holding well so far, why the pretty hard drop?
👍️0
wiredawg wiredawg 3 years ago
Why are you surprised? Serious question, not being impudent...
👍️0
rynlrt rynlrt 3 years ago
200 million dollar offering. Won't be surprised to see it drop pretty hard when the market opens
👍️0
Fofo812 Fofo812 3 years ago
Surprised it held up this long
👍️0
crudeoil24 crudeoil24 3 years ago
Large tutes holdings. Some taking huge gains before years end.
👍️0
rynlrt rynlrt 3 years ago
Not sure this kind of gain is sustainable. May see a big pullback
👍️0
Fofo812 Fofo812 3 years ago
3rd post
👍️0
crudeoil24 crudeoil24 3 years ago
Krystal Biotech shares are trading higher after the company announced its GEM-3 trial met its primary endpoint.
👍️0
Trophy Trophy 5 years ago
..
👍️0

Your Recent History

NASDAQ
KRYS
Krystal Biotech
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

United States
Company
Business
Popular
Get The App
App Store
Google Play

Support: 1-888-992-3836 | support@advfn.com

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

© 2024 ADVFN PLC - All Rights Reserved